Page last updated: 2024-12-06

phenylisopropyladenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID93205
CHEMBL ID139000
CHEBI ID184076
SCHEMBL ID8907369
MeSH IDM0016566

Synonyms (57)

Synonym
(r)-n6-phenylisopropyladenosine
(-)-(phenylisopropyl)adenosine
brn 4912716
r(-)-n(sup 6)-2-phenylisopropyladenosine
phenylisopropyladenosine, l-
l-2-n6-(phenylisopropyl)adenosine
(r)-pia
einecs 254-028-5
adenosine, n-(1-methyl-2-phenylethyl)-, (r)-
l-phenylisopropyladenosine
l-pia
(r)-n-(1-methyl-2-phenylethyl)adenosine
n6-d-phenylisopropyladenosine
(r)-n6-(2-phenylisopropyl)adenosine
l-n(sup 6)-phenylisopropyladenosine
(-)-n-(alpha-methylphenethyl)adensoine
n6-(r)-phenylisopropyladenosine
(-)-n6-(2-phenylisopropyl)adenosine
MLS002153162
smr001230656
gtpl414
PDSP2_001013
PDSP2_000442
(-)-n6-(2-phenylisopropyl)adenosine, solid
PDSP1_000297
PDSP1_001029
PDSP1_000444
29-36-7
NCGC00162295-02
PDSP2_000295
NCGC00162295-01
NCGC00162295-03
r-n6-(phenylisopropyl)adenosine
CHEMBL139000 ,
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-((r)-1-phenylpropan-2-ylamino)-9h-purin-9-yl)-tetrahydrofuran-3,4-diol
n6-[(r)-1-methyl-2-phenylethyl]ado (r-pia)
bdbm50118810
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(2r)-1-phenylpropan-2-yl]amino]purin-9-yl]oxolane-3,4-diol
38594-96-6
CHEBI:184076
HMS2235H09
SCHEMBL8907369
(-)-n6-(2-phenylisopropyl)-adenosine
REGID_FOR_CID_93205
r-(-)-n6-(2-phenyl-isopropyl)adenosine
AKOS030530544
th-162
(-)-n6-(2-phenylisopropyl) adenosine
DTXSID50926443
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-(((r)-1-phenylpropan-2-yl)amino)-9h-purin-9-yl)tetrahydrofuran-3,4-diol
Q27088620
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-((r)-1-phenylpropan-2-ylamino)-9h-purin-9-yl)tetrahydrofuran-3,4-diol
NCGC00162295-05
(r)?- pia
(r)?-pia
(r)?-?pia
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-{[(2r)-1-phenylpropan-2-yl]amino}-9h-purin-9-yl)oxolane-3,4-diol

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" When measured in the presence of antagonists, the dose-response curves of NECA-induced inhibition of forskolin-stimulated cAMP accumulation were right-shifted."( Molecular cloning and characterization of the human A3 adenosine receptor.
Jacobson, MA; Johnson, RG; Linden, J; Salvatore, CA; Taylor, HE, 1993
)
0.29
" Neuroprotective properties assessed after postischemic dosing in a Mongolian gerbil severe temporary forebrain ischemia paradigm, using hippocampal CA1 damage endpoints, and the efficacy of these agonists in an A(1) functional assay show similarities to some reference adenosine agonists."( N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
Hansen, AJ; Judge, ME; Knutsen, LJ; Lau, J; Petersen, H; Shalmi, M; Sheardown, MJ; Thomsen, C; Weis, JU, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
adenosine A1 receptor agonistAn agonist at the A1 receptor.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
hydrocarbyladenosine
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
purine nucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency3.54810.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency7.10770.004110.890331.5287AID493106; AID493107; AID504466; AID504467
USP1 protein, partialHomo sapiens (human)Potency15.84890.031637.5844354.8130AID743255
GLS proteinHomo sapiens (human)Potency17.78280.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency23.10930.000811.382244.6684AID686979
regulator of G-protein signaling 4Homo sapiens (human)Potency1.49890.531815.435837.6858AID504845
arylsulfatase AHomo sapiens (human)Potency1.06911.069113.955137.9330AID720538
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.31620.035520.977089.1251AID504332
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency16.36010.01262.451825.0177AID485313
vasopressin V1b receptorHomo sapiens (human)Potency21.86210.194416.018043.6206AID492948
chromobox protein homolog 1Homo sapiens (human)Potency0.00530.006026.168889.1251AID488953
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency125.89203.548119.542744.6684AID743266
importin subunit beta-1 isoform 1Homo sapiens (human)Potency6.51315.804836.130665.1308AID540253
ras-related protein Rab-9AHomo sapiens (human)Potency16.36010.00022.621531.4954AID485297
snurportin-1Homo sapiens (human)Potency6.51315.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency6.51315.804816.996225.9290AID540253
relaxin receptor 1 isoform 1Homo sapiens (human)Potency8.35580.038814.350143.6206AID2676; AID489012
relaxin receptor 2 isoform 1Homo sapiens (human)Potency43.62060.048815.980148.9431AID489043
Ataxin-2Homo sapiens (human)Potency8.91250.011912.222168.7989AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
high affinity choline transporter 1 isoform aHomo sapiens (human)IC50 (µMol)1.86130.00036.210228.8403AID504840; AID588401
ReninHomo sapiens (human)Ki0.00060.00001.80787.4000AID195542
Adenosine receptor A3Homo sapiens (human)Ki0.01110.00000.930610.0000AID1280099; AID281463; AID34574
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)0.02940.00020.552110.0000AID31410; AID31412; AID31414; AID34007
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.02480.00011.20929.9700AID195542; AID195543; AID195544; AID196738; AID31854; AID32015; AID32027; AID32029; AID32031; AID32177; AID32179; AID32182; AID32352; AID32353; AID32360; AID32361; AID32482; AID32503
Adenosine receptor A1Bos taurus (cattle)Ki0.00820.00000.71316.0000AID32002; AID32006; AID32007
Adenosine receptor A3Rattus norvegicus (Norway rat)IC50 (µMol)0.04970.00070.03740.0957AID34007
Adenosine receptor A3Rattus norvegicus (Norway rat)Ki0.01660.00030.91969.0000AID195542; AID195543; AID195544; AID196738; AID33333
Adenosine receptor A2aHomo sapiens (human)Ki1.11130.00001.06099.7920AID281461; AID30654; AID33928
Adenosine receptor A2bHomo sapiens (human)Ki1.70000.00021.635210.0000AID30654
Adenosine receptor A2bRattus norvegicus (Norway rat)IC50 (µMol)0.28980.00240.68169.0000AID33405; AID34007
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki2.68390.00061.353610.0000AID195542; AID195543; AID195544; AID196738; AID30656; AID33440; AID33573; AID33590; AID33726; AID33733; AID33901
Adenosine receptor A1Homo sapiens (human)IC50 (µMol)0.83000.00020.68187.7010AID751702
Adenosine receptor A1Homo sapiens (human)Ki0.16470.00020.931610.0000AID1280098; AID281459; AID751702
Adenosine receptor A2aRattus norvegicus (Norway rat)IC50 (µMol)0.28980.00120.48289.0000AID33405; AID34007
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki2.48820.00021.494010.0000AID195542; AID195543; AID195544; AID196738; AID30656; AID33440; AID33573; AID33590; AID33726; AID33733; AID33800; AID33901
Adenylate cyclase type 5Rattus norvegicus (Norway rat)Ki0.00870.00140.04950.1180AID34574
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A3Homo sapiens (human)EC50 (µMol)0.02700.00010.42587.9800AID34265
Adenosine receptor A2aHomo sapiens (human)EC50 (µMol)0.95000.00030.708110.0000AID30634
Adenosine receptor A2bHomo sapiens (human)EC50 (µMol)1.31500.00030.946110.0000AID281466; AID30634
Adenosine receptor A1Homo sapiens (human)EC50 (µMol)1.20000.00010.99169.8000AID380497
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)EC25 (µMol)0.01000.00300.01420.0350AID175310
Adenosine receptor A2aHomo sapiens (human)Affinity constant30.00000.20006.028610.0000AID33909
Adenosine receptor A2bHomo sapiens (human)Affinity constant30.00000.20006.028610.0000AID33909
Adenosine receptor A2bRattus norvegicus (Norway rat)EC25 (µMol)0.01000.00300.01420.0350AID175310
Adenosine receptor A2bRattus norvegicus (Norway rat)Ratio0.12400.00330.82929.6000AID33746
Adenosine receptor A1Homo sapiens (human)Affinity constant0.00300.00301.069110.0000AID30353
Adenosine receptor A2aRattus norvegicus (Norway rat)EC25 (µMol)0.01000.00300.01420.0350AID175310
Adenosine receptor A2aRattus norvegicus (Norway rat)Ratio0.12400.00330.82309.6000AID33746
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (129)

Processvia Protein(s)Taxonomy
kidney developmentReninHomo sapiens (human)
mesonephros developmentReninHomo sapiens (human)
angiotensin maturationReninHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionReninHomo sapiens (human)
proteolysisReninHomo sapiens (human)
regulation of blood pressureReninHomo sapiens (human)
male gonad developmentReninHomo sapiens (human)
hormone-mediated signaling pathwayReninHomo sapiens (human)
response to lipopolysaccharideReninHomo sapiens (human)
response to immobilization stressReninHomo sapiens (human)
drinking behaviorReninHomo sapiens (human)
regulation of MAPK cascadeReninHomo sapiens (human)
cell maturationReninHomo sapiens (human)
amyloid-beta metabolic processReninHomo sapiens (human)
response to cAMPReninHomo sapiens (human)
response to cGMPReninHomo sapiens (human)
cellular response to xenobiotic stimulusReninHomo sapiens (human)
juxtaglomerular apparatus developmentReninHomo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Bos taurus (cattle)
response to purine-containing compoundAdenosine receptor A1Bos taurus (cattle)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
temperature homeostasisAdenosine receptor A1Homo sapiens (human)
response to hypoxiaAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processAdenosine receptor A1Homo sapiens (human)
negative regulation of acute inflammatory responseAdenosine receptor A1Homo sapiens (human)
negative regulation of leukocyte migrationAdenosine receptor A1Homo sapiens (human)
positive regulation of peptide secretionAdenosine receptor A1Homo sapiens (human)
positive regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
negative regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
regulation of glomerular filtrationAdenosine receptor A1Homo sapiens (human)
protein targeting to membraneAdenosine receptor A1Homo sapiens (human)
phagocytosisAdenosine receptor A1Homo sapiens (human)
inflammatory responseAdenosine receptor A1Homo sapiens (human)
signal transductionAdenosine receptor A1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
cell-cell signalingAdenosine receptor A1Homo sapiens (human)
nervous system developmentAdenosine receptor A1Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A1Homo sapiens (human)
response to inorganic substanceAdenosine receptor A1Homo sapiens (human)
negative regulation of glutamate secretionAdenosine receptor A1Homo sapiens (human)
response to purine-containing compoundAdenosine receptor A1Homo sapiens (human)
lipid catabolic processAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicAdenosine receptor A1Homo sapiens (human)
positive regulation of nucleoside transportAdenosine receptor A1Homo sapiens (human)
negative regulation of neurotrophin productionAdenosine receptor A1Homo sapiens (human)
positive regulation of protein dephosphorylationAdenosine receptor A1Homo sapiens (human)
vasodilationAdenosine receptor A1Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleepAdenosine receptor A1Homo sapiens (human)
negative regulation of apoptotic processAdenosine receptor A1Homo sapiens (human)
positive regulation of potassium ion transportAdenosine receptor A1Homo sapiens (human)
positive regulation of MAPK cascadeAdenosine receptor A1Homo sapiens (human)
negative regulation of hormone secretionAdenosine receptor A1Homo sapiens (human)
cognitionAdenosine receptor A1Homo sapiens (human)
leukocyte migrationAdenosine receptor A1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
positive regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
regulation of sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicAdenosine receptor A1Homo sapiens (human)
fatty acid homeostasisAdenosine receptor A1Homo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A1Homo sapiens (human)
long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
mucus secretionAdenosine receptor A1Homo sapiens (human)
negative regulation of mucus secretionAdenosine receptor A1Homo sapiens (human)
triglyceride homeostasisAdenosine receptor A1Homo sapiens (human)
regulation of cardiac muscle cell contractionAdenosine receptor A1Homo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic potentiationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
aspartic-type endopeptidase activityReninHomo sapiens (human)
signaling receptor bindingReninHomo sapiens (human)
insulin-like growth factor receptor bindingReninHomo sapiens (human)
protein bindingReninHomo sapiens (human)
peptidase activityReninHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor bindingAdenosine receptor A1Homo sapiens (human)
purine nucleoside bindingAdenosine receptor A1Homo sapiens (human)
protein bindingAdenosine receptor A1Homo sapiens (human)
heat shock protein bindingAdenosine receptor A1Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingAdenosine receptor A1Homo sapiens (human)
heterotrimeric G-protein bindingAdenosine receptor A1Homo sapiens (human)
protein heterodimerization activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
extracellular regionReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membraneReninHomo sapiens (human)
apical part of cellReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
basolateral plasma membraneAdenosine receptor A1Homo sapiens (human)
axolemmaAdenosine receptor A1Homo sapiens (human)
asymmetric synapseAdenosine receptor A1Homo sapiens (human)
presynaptic membraneAdenosine receptor A1Homo sapiens (human)
neuronal cell bodyAdenosine receptor A1Homo sapiens (human)
terminal boutonAdenosine receptor A1Homo sapiens (human)
dendritic spineAdenosine receptor A1Homo sapiens (human)
calyx of HeldAdenosine receptor A1Homo sapiens (human)
postsynaptic membraneAdenosine receptor A1Homo sapiens (human)
presynaptic active zoneAdenosine receptor A1Homo sapiens (human)
synapseAdenosine receptor A1Homo sapiens (human)
dendriteAdenosine receptor A1Homo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (184)

Assay IDTitleYearJournalArticle
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID33022Ability to displace [3H]-CGS- 21680 from Adenosine A2A receptor of rat brain striatum at 10e-5 M2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID175310Enhancement of coronary flow (A2 response) in isolated rat heart preparation1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID196931Antagonist binding of N6-cyclohexyl-[3H]-adenosine to rat testes1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID33928Inhibitory activity at Adenosine A2A receptor by inhibition of [3H]-CGS- 21680 binding to bovine striatal membranes.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID32353Affinity for the Adenosine A1 receptor in the presence of GTP (A1+GTP) by using [3H]-DPCPX as radioligand1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.
AID33333Affinity to Adenosine A3 receptor of rat testis membrane using [3H](R)-PIA with 150 nM DPCPX2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID32031Binding affinity against low affinity component of adenosine A1 receptors from rat brain membranes using [3H]-DPCPX1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID281469Maximum efficacy at human recombinant adenosine A3 receptor expressed in CHO cells assessed as inhibition of cAMP production at 10 uM relative to NECA2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor.
AID330859Agonist activity human adenosine A2B receptor expressed in CHO cells assessed as stimulation of adenylate cyclase relative to NECA2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists.
AID229446Relative binding to A2 and A1 receptors (ratio of Ki)1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.
AID235884Ratio of binding affinities for A2 and A1 receptors1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Ribose-modified adenosine analogues as adenosine receptor agonists.
AID330858Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as stimulation of adenylate cyclase2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists.
AID33917Ability to displace the specific binding of [3H]-CGS- to adenosine A2A receptor form bovine brain striatal membranes2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.
AID32482Displacement of [3H]R-PIA from adenosine A1 receptor of Wistar rat forebrain1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID32002Inhibitory activity at Adenosine A1 receptor by inhibition of [3H]CHA binding to bovine brain cortical membranes.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID32179Inhibition of [3H]- (R)-P1A binding to adenosine A1 receptor1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.
AID31854Inhibition of [3H]CHA (N6-cyclohexyl adenosine) to rat brain membrane Adenosine A1 receptor2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID751769Displacement of [3H]DPCPX from human recombinant adenosine receptor A1 expressed in CHO cells at 10 uM after 90 mins relative to control2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID32206Displacement of [3H]CHA from adenosine A1 receptor of rat whole brain1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.
AID116532CNS activity measured using screen test failure1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Ribose-modified adenosine analogues as adenosine receptor agonists.
AID33588Binding affinity towards adenosine A2 receptor on rat striatal membrane using [3H]NECA as radioligand1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID33567Binding affinity to A2 adenosine receptor in rat striatal membranes by [3H]NECA (1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-beta-D-ribofuranuronamide) displacement.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID33440Binding affinity at adenosine A2 receptor from rat striatal membranes by [3H]NECA displacement.1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.
AID32029Binding affinity against high affinity component of adenosine A1 receptors from rat brain membranes using [3H]DPCPX1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID33903Ratio of binding potencies at adenosine A2AR and AIAR receptors1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.
AID33490Selectivity for Adenosine A3 over Adenosine A1 receptor2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID33800Binding affinity against Adenosine A2A receptor by using [3H]CGS-21680 as radioligand1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.
AID1573510Agonist activity at adenosine A1 receptor (unknown origin) expressed in FlpIn-CHO cells assessed as increase in cAMP accumulation2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID53750In vitro inhibition of isoprenaline-stimulated cAMP accumulation in DDT1-MF2 cells (measured by adenosine A1 functional assay)1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID33909Affinity constant for A2 receptor control of adenylate cyclase in adipocytes, heart and brain cells1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID195544Antagonist binding of N6-cyclohexyl-[3H]-adenosine to rat brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID32195Binding affinity towards adenosine A1 receptor on rat whole brain membrane using [3H]N6-cyclohexyladenosine1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID233377Inhibitory selectivity at Adenosine 2A receptor compared to Adenosine 1 receptor.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID34272Percent efficacy against human Adenosine A3 receptor expressed in CHO cell2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.
AID184466Mean blood pressure(MBP) at an infused iv dose of agonist administered intravenously 0 mg/kg/h1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID32006Intrinsic activity towards Adenosine A1 receptor as displacement of [3H]DPCPX from bovine cortical membranes without GTP2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists.
AID1573511Agonist activity at adenosine A1 receptor (unknown origin) expressed in FlpIn-CHO cells assessed as increase in ERK1/2 phosphorylation2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID281466Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as stimulation of cAMP production2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor.
AID131363Effect on Motor activity in mouse following i.p. administration.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID34007Displacement of [3H]CHA from rat brain adenosine receptor1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
C4-substituted 1-beta-D-ribofuranosylpyrazolo[3,4-d]pyrimidines as adenosine agonist analogues.
AID32182Displacement of [3H]PIA from adenosine A1 receptor of rat brain membranes1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.
AID233029A1 selectivity as ratio of EC50 at A2 receptor to IC50 at A1 receptor1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.
AID751702Displacement of [3H]DPCPX from human recombinant adenosine receptor A1 expressed in CHO cells after 90 mins2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID25506Index of hydrophobicity (k')1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID229799Ratio of Ki at adenosine A2 and A1 receptors1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID34265Effect on forskolin-stimulated cyclic AMP production in intact chinese hamster ovary (CHO) cell expressing the human Adenosine A3 receptor2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.
AID233378Inhibitory selectivity at Adenosine A3 receptor compared to Adenosine 1 receptor.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID32169Binding affinity for adenosine A1 receptor in rat brain membranes using [3H]CHA as radioligand1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Ribose-modified adenosine analogues as adenosine receptor agonists.
AID42825Antagonist binding of N6-cyclohexyl-[3H]-adenosine to bovine brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID30497Molar potency ratio (MPR) against A2 adenosine receptor of coronary artery1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID32352Affinity for the Adenosine A1 receptor in the absence of GTP (A1-GTP) by using [3H]DPCPX as radioligand1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.
AID75123Reduction in hippocampal cell death by compound administered 30 min after a period of severe forebrain ischemia in the Mongolian gerbil at 0.3 mg/kg1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID33573Binding affinity against adenosine A2 receptor from rat striatal membranes with 50 nM CPA using [3H]-NECA1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID32503Inhibition of binding of [3H]N6-cyclohexyladenosine to adenosine A1 receptor of rat whole brain membranes.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
AID195501Percent reduction in blood pressure in an anesthetized rat 5 min after intravenous administration of 0.1 mg/kg of compound1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID32007Intrinsic activity towards Adenosine A1 receptor as displacement of [3H]DPCPX from bovine cortical membranes with 1 mM GTP2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists.
AID233379Inhibitory selectivity at Adenosine A3 receptor compared to Adenosine 2A receptor.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID1280099Binding affinity to adenosine A3 receptor (unknown origin)2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
AID227156Selectivity as A1 adenosine receptors(high affinity) using [3H]-DPCPX compared to A2 adenosine receptors using [3H]NECA in rat striatal membranes1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID17397425% reduction in blood pressure in the rat.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID25101Ionisation constant (pKa)1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID78487Antagonist binding of N6-cyclohexyl-[3H]-adenosine to guinea pig brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID130702In vivo inhibition of spontaneous locomotor activity of mouse by the compound 30 min after intraperitoneal administration.1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID30491Binding affinity against A2 adenosine receptor1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID33726Binding affinity for Adenosine A2 receptor in corpora striata of rats using [3H]NECA1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID31414Inhibition of Adenylate cyclase activity in rat fat cell membrane at adenosine A1 receptor1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.
AID32639Ratio of IC50 values for A1 receptor binding to that of A2 receptor1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID227155Selectivity as A1 adenosine receptors(high affinity) using [3H]CCPA compared to A2 adenosine receptors using [3H]-NECA in rat striatal membranes1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID31866Binding affinity at adenosine A1 receptor from rat brain membranes by [3H]N6-cyclohexyladenosine displacement.1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.
AID232472Selectivity ratio for A1 receptor to that of A2 receptor in vitro in rat tissues1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
AID33405Concentration required for 50% inhibition of [3H]NECA binding on rat brain adenosine A2 receptor1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID32361Evaluated for the binding affinity towards the Adenosine A1 receptor in corpora striata of rats using [3H]CHA as radioligand.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID33733Inhibition of binding of [3H]NECA to adenosine A2 receptor of rat striatal membranes.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
AID33901Inhibition of [3H]- NECA binding to adenosine receptor A21991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.
AID1280098Binding affinity to adenosine A1 receptor (unknown origin)2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
AID33491Selectivity towards Adenosine A3 receptor to Adenosine A2A receptor2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID34117Ability to displace the specific binding of [3H](R)-PIA to adenosine A3 receptor from rat testis membranes2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.
AID281459Displacement of [3H]CPPA from human adenosine A1 receptor expressed in CHO cells2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor.
AID196738Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat fat1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID73904Negative inotropy effect in isolated guinea pig atria. 1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID184469Mean blood pressure(MBP) at an infused iv dose of agonist administered intravenously 0.05 mg/kg/h1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID231269Ratio of binding affinity against A2 and A1 receptors1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.
AID30791Maximal stimulation of adenylate cyclase activity relative to NECA for A2-receptor. (Stimulation by NECA=250+/-30%)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.
AID195543Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID116534Dose required to inhibit mouse locomotor activity by 60%1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Ribose-modified adenosine analogues as adenosine receptor agonists.
AID33582Binding affinity for adenosine A2 receptor in rat striatal membranes using [3H]NECA as radioligand1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Ribose-modified adenosine analogues as adenosine receptor agonists.
AID33019Selectivity for Adenosine A2A over Adenosine A1 receptor2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID33590Displacement of [3H]-NECA from adenosine A2 receptor of rat striatal membrane1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.
AID30495Association constant against A2 adenosine receptor1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID235521Selectivity, ratio of affinity towards adenosine A3 to A12000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.
AID194218Change in heart rate was expressed in percent at at a dose 0.005 mg/kg iv in anesthetized rat1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID184468Mean blood pressure(MBP) at an infused iv dose of agonist administered intravenously 0.01 mg/kg/h1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID233030A1 selectivity as ratio of Ki for A2 receptor to Ki for A1 receptor1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.
AID31976Ability to displace the specific binding of [3H]CHA to adenosine A1 receptor from bovine brain cortical membranes2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.
AID30654Binding affinity against adenosine A2 receptor from human platelet membranes using [3H]NECA1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID32027Binding affinity against adenosine A1 receptors from rat brain membranes using [3H]CCPA1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID131362Effect on Ataxia in mouse following i.p. administration.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID130698In vivo inhibition of DMCM-induced seizures in mouse by the compound 30 min after intraperitoneal administration1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID173802Compound was evaluated for Cardiovascular activity (as 20% decrease in blood pressure) in rats1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Ribose-modified adenosine analogues as adenosine receptor agonists.
AID235522Selectivity, ratio of affinity towards adenosine A3 to A2A2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.
AID25507HPLC capacity factor (k')1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID33482Inhibitory activity against Adenosine A3 receptor by inhibiting specific [3H](R)-PIA binding to rat testis membranes1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID281461Displacement of [3H]CGS-21680 from human adenosine A2A receptor expressed in CHO cells2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor.
AID228918Molar potency ratio was evaluated1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID235520Selectivity, ratio of affinity towards adenosine A2A to A12000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.
AID173805Compound was evaluated for Cardiovascular activity (as 20% decrease in rate) in rats1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Ribose-modified adenosine analogues as adenosine receptor agonists.
AID33752Ratio of A2 to A1.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID33746Binding affinity against adenosine A2 receptor using [3H]- NECA as radioligand1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID184467Mean blood pressure(MBP) at an infused iv dose of agonist administered intravenously 0.005 mg/kg/h1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID34158Inhibition of adenyl cyclase via P site in adipocytes; Inactive1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID31412Evaluated for the binding affinity towards the Adenosine A1 receptor in cerebral cortices of Sprague-Dawley male rats using [3H]CHA as radioligand.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID34574Affinity for human Adenosine A3 receptor expressed in CHO cell2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.
AID32177Binding affinity against adenosine A1 receptor using [3H]-CHA or [3H]PIA as radioligand1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID31410Concentration required for 50% inhibition of [3H]-CHA binding on rat brain adenosine A1 receptor1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID175313Reduction of heart rate (A1 response) in isolated rat heart preparation1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID32015Binding affinity to adenosine A1 receptor in rat whole brain membranes by [3H]N6-cyclohexyladenosine displacement.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID32781Effective concentration against A2AR mediated P12 adenylatencyclase activity1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.
AID179545GTP shift was determined in rat1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.
AID30328Maximal inhibition of adenylate cyclase activity relative to R-PIA for Adenosine A1 receptor (Inhibition by R-PIA=53+/-10%)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.
AID30350Displacement of [3H]-CGS- 21680 from adenosine A2A receptor of rat striatal tissue1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID30656Displacement of [3H]NECA from A2-receptor of rat striatal membranes1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.
AID281463Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cells2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor.
AID30634Stimulation of adenylate cyclase activity in human platelet membrane at A2 receptor1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.
AID195542Antagonist binding of 2-chloro-[3H]-adenosine to rat brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID32360Binding affinity for Adenosine A1 receptor in cerebral cortices of Sprague-Dawley male rats using [3H]-CHA1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID380497Displacement of [3H]DPCPX from human recombinant adenosine A1 receptor expressed in CHO cells2006Journal of natural products, Mar, Volume: 69, Issue:3
Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.
AID30353Affinity constant for inhibition of A1 receptor control of adenylate cyclase in adipocytes, heart and brain cells1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1345831Rat A3 receptor (Adenosine receptors)1993Pharmacology, , Volume: 46, Issue:2
Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors.
AID1345685Human A1 receptor (Adenosine receptors)1994The Journal of biological chemistry, Jan-28, Volume: 269, Issue:4
A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding.
AID1345685Human A1 receptor (Adenosine receptors)2004Biochemical pharmacology, Nov-15, Volume: 68, Issue:10
2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors.
AID1345822Human A3 receptor (Adenosine receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Nov-01, Volume: 90, Issue:21
Molecular cloning and characterization of the human A3 adenosine receptor.
AID1345685Human A1 receptor (Adenosine receptors)1999The Journal of biological chemistry, Feb-05, Volume: 274, Issue:6
Identification of the adenine binding site of the human A1 adenosine receptor.
AID1345685Human A1 receptor (Adenosine receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.
AID1345822Human A3 receptor (Adenosine receptors)2000Molecular pharmacology, May, Volume: 57, Issue:5
[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
AID1345618Human A2A receptor (Adenosine receptors)1997British journal of pharmacology, Jun, Volume: 121, Issue:3
Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
AID1345831Rat A3 receptor (Adenosine receptors)1994The Journal of biological chemistry, Oct-07, Volume: 269, Issue:40
Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors.
AID1345630Rat A1 receptor (Adenosine receptors)1993Pharmacology, , Volume: 46, Issue:2
Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors.
AID1345721Human A2B receptor (Adenosine receptors)2000Molecular pharmacology, Dec, Volume: 58, Issue:6
Why are A(2B) receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A(2B) receptor for 2-(1-Hexynyl)adenosine.
AID1345618Human A2A receptor (Adenosine receptors)1995The Journal of biological chemistry, Jun-09, Volume: 270, Issue:23
Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor.
AID1345685Human A1 receptor (Adenosine receptors)1994The Journal of biological chemistry, Dec-23, Volume: 269, Issue:51
Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor.
AID1345822Human A3 receptor (Adenosine receptors)2004Biochemical pharmacology, Nov-15, Volume: 68, Issue:10
2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors.
AID1345721Human A2B receptor (Adenosine receptors)1999Molecular pharmacology, Oct, Volume: 56, Issue:4
Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells.
AID1345822Human A3 receptor (Adenosine receptors)1997Neuropharmacology, Sep, Volume: 36, Issue:9
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists.
AID1345721Human A2B receptor (Adenosine receptors)1980Canadian journal of physiology and pharmacology, Jun, Volume: 58, Issue:6
Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists.
AID1345618Human A2A receptor (Adenosine receptors)1999Biochemical pharmacology, Jan-01, Volume: 57, Issue:1
Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors.
AID1345721Human A2B receptor (Adenosine receptors)2001Biochemical pharmacology, Mar-15, Volume: 61, Issue:6
[3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors.
AID1345618Human A2A receptor (Adenosine receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.
AID1345735Mouse A2B receptor (Adenosine receptors)1994Biochemical pharmacology, Mar-02, Volume: 47, Issue:5
Functional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts.
AID1345721Human A2B receptor (Adenosine receptors)2005Biochemical pharmacology, Nov-25, Volume: 70, Issue:11
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors.
AID1345822Human A3 receptor (Adenosine receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.
AID1345618Human A2A receptor (Adenosine receptors)2004Biochemical pharmacology, Nov-15, Volume: 68, Issue:10
2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors.
AID1345690Rat A2A receptor (Adenosine receptors)1993Pharmacology, , Volume: 46, Issue:2
Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (20.63)18.7374
1990's21 (33.33)18.2507
2000's15 (23.81)29.6817
2010's9 (14.29)24.3611
2020's5 (7.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (6.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other59 (93.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]